Vivani Medical, Inc. — fact timeline

Vivani Medical, Inc. issued 1,351,351 shares of common stock of common stock to entity affiliated with Gregg Williams, Chairman of the Company’s board of directors for purchase price of $1.48 per share, gross proceeds of approximately $2.0 million.

“Vivani Medical, Inc. (the “Company”) entered into a Share Purchase Agreement, dated January 25 , 2026 (the “Purchase Agreement”), with an entity affiliated with Gregg Williams, Chairman of the Company’s board of directors (the “Purchaser”) for the purchase of an aggregate of 1,351,351 shares of common stock, par value of $0.0001 per share (“Common Stock”) of the Company at a purchase price of $1. 4 8 per share (the “Private Placement Shares”), the last reported sale price of the Common Stock on January 2 3 , 2026 . This private placement of Common Stock resulted in gross proceeds of approximately $ 2.0 million to the Company.”

Vivani Medical, Inc. entered into Placement Agency Agreement with ThinkEquity LLC (the “Agent”) valued at gross proceeds of approximately $2.5 million (effective 2026-01-25).

“the Company also entered into a Placement Agency Agreement, dated January 25 , 2026 (the “Placement Agency Agreement”) with ThinkEquity LLC (the “Agent”) relating to the sale by the Company of 1,689,200 shares of the Company’s Common Stock”

Vivani Medical, Inc. entered into Share Purchase Agreement with an entity affiliated with Gregg Williams, Chairman of the Company’s board of directors (the “Purchaser”) valued at gross proceeds of approximately $2.0 million (effective 2026-01-25).

“Vivani Medical, Inc. (the “Company”) entered into a Share Purchase Agreement, dated January 25 , 2026 (the “Purchase Agreement”), with an entity affiliated with Gregg Williams, Chairman of the Company’s board of directors (the “Purchaser”) for the purchase of an aggregate of 1,351,351 shares of common stock”

Anthony Baldor was appointed as Chief Financial Officer at Vivani Medical, Inc..

“On June 11, 2025, the board of directors (the “Board”) of the Company appointed Anthony Baldor, to serve as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective June 15, 2025.”

Brigid Makes resigned as Chief Financial Officer at Vivani Medical, Inc..

“On June 10, 2025, Brigid Makes notified Vivani Medical, Inc. (the “Company”) of her decision to resign from her role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, of the Company, effective as of June 15, 2025.”

Vivani Medical, Inc. reported first quarter ended March 31, 2024 results: net income Net loss during the three months ended March 31, 2024 was $6.0 million.

“Net loss during the three months ended March 31, 2024 was $6.0 million”

Vivani Medical, Inc. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $75.0 million (effective 2024-04-22).

“On April 22, 2024, Vivani Medical, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Agreement”) with Jefferies LLC (“Jefferies”), under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $75.0 million through Jefferies as its sales agent.”

Daniel Bradbury was appointed as Director at Vivani Medical, Inc..

“unanimously appointed Daniel Bradbury to fill a newly created vacancy on the Board”

Vivani Medical, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2024-03-01).

“The Company also entered into a Placement Agency Agreement with Maxim Group LLC (the “Placement Agency Agreement,” and together with the Securities Purchase Agreement, the “Agreements”), who is acting as the sole placement agent for the Offering.”

Vivani Medical, Inc. entered into Securities Purchase Agreement with an institutional investor valued at approximately $15.0 million (effective 2024-03-01).

“On March 1, 2024, Vivani Medical, Inc. (the “Company”) entered into a Securities Purchase Agreement with an institutional investor (the “Securities Purchase Agreement”) relating to the issuance of 3,947,368 shares of the Company’s common stock, par value of $0.0001 per share (the “Common Stock”) and warrants to purchase up to an aggregate of 3,947,368 shares of Common Stock (the “Warrant”), to such investor at a purchase price of $3.80 per share and accompanying warrant in a registered direct offering (the “Offering”).”

Vivani Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 26, 2023, Vivani Medical, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for 30 consecutive trading days from November 9, 2023 through December 21, 2023, the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The N”

Scott Dunbar departed as Named Executive Officer at Vivani Medical, Inc..

“the Company terminated without cause the employment of Scott Dunbar, a named executive officer in the Company’s 2023 proxy statement and former Acting Chief Executive Officer of the Company’s predecessor, Second Sight Medical Products, Inc., effective as of November 20, 2023”

Vivani Medical, Inc. reported financial results for third quarter of 2023.

“today reported financial results for the third quarter of 2023 and provided a business update.”

Vivani Medical, Inc. amended Amendment with Cortigent, Inc. valued at $1,500,000 (effective 2023-08-25).

“On August 25, 2023, the Company and Cortigent, Inc. ("Cortigent"), a wholly owned subsidiary of the Company entered into an Amendment 1 (the "Amendment") to the Transition Funding, Support and Services Agreement dated March 19, 2023 (the "TFSSA").”

Vivani Medical, Inc.: Reincorporated from California to Delaware, resulting in adoption of new Certificate of Incorporation and Bylaws (effective 2023-07-06).

“As disclosed in Item 3.03 above, effective July 6, 2023, the Company changed its state of incorporation from California to Delaware pursuant to the Plan of Conversion. As of that date, the rights of the Company’s stockholders began to be governed by Delaware corporation laws, the Certificate of Incorporation, and the Bylaws.”

Vivani Medical, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-15 meeting.

“Proposal 5 : The stockholders, on a non-binding advisory basis, approved the compensation of the Company’s named executive officers, as set forth below: Votes Non-Votes 28,751,018. 256,320 70,303. 6,471,052”

Vivani Medical, Inc. shareholders approved Inclusion of provision requiring exclusive federal forum for Securities Act claims at the 2023-06-15 meeting.

“Proposal 4F : The stockholders approved a proposal to include a provision of the Delaware Charter requiring any complaint asserting a cause of action under the Securities Act of 1933 to be brought exclusively in the federal district courts of the United States, unless the Company consents in writing to the selection of an alternative forum, as set forth below: Votes Non-Votes 27,315,559 116,065 1,646,017 6,471,052”

Vivani Medical, Inc. shareholders approved Inclusion of provision for exclusive forum for intra-corporate claims in Delaware Court of Chancery at the 2023-06-15 meeting.

“Proposal 4E : The stockholders approved a proposal to include a provision of the Delaware Charter providing that, unless Vivani Delaware consents in writing to the selection of an alternate forum, certain intra-corporate claims may be brought exclusively in the Delaware Court of Chancery (or, if such court lacks subject matter jurisdiction, the other state or federal courts in the State of Delaware), as set forth below: Votes Non-Votes 27,299,674 130,461 1,647,506 6,471,052”

Vivani Medical, Inc. shareholders approved Inclusion of provisions disallowing action by written consent of stockholders at the 2023-06-15 meeting.

“Proposal 4D : The stockholders approved a proposal to include provisions of the Delaware Charter and Bylaws disallowing action by written consent of stockholders, as set forth below: Votes Non-Votes 26,695,069 666,911 1,715,661 6,471,052”

Vivani Medical, Inc. shareholders approved Inclusion of provision in Delaware Bylaws permitting only the Board to call special meetings at the 2023-06-15 meeting.

“Proposal 4C : The stockholders approved a proposal to include a provision of the Company’s new Bylaws in Delaware (the “Delaware Bylaws”) permitting only the Board to call special meetings, as set forth below: Votes Non-Votes 26,713,084 723,481 1,641,076 6,471,052”

Vivani Medical, Inc. shareholders approved Inclusion of provision in Delaware Charter limiting right to remove directors without cause at the 2023-06-15 meeting.

“Proposal 4B : The stockholders approved a proposal to include a provision of the Delaware Charter limiting the Company’s stockholders’ right to remove directors without cause, as set forth below: Votes Non-Votes 28,074,961 988,192 14,488 6,471,052”

Vivani Medical, Inc. shareholders approved Inclusion of provision in Delaware Charter disallowing cumulative voting at the 2023-06-15 meeting.

“Proposal 4A : The stockholders approved a proposal to include a provision of the Company’s new Certificate of Incorporation in Delaware (the “Delaware Charter”) disallowing cumulative voting, as set forth below: Votes Non-Votes 28,761,039 218,095 98,507 6,471,052”

Vivani Medical, Inc. shareholders approved Approval of reincorporation from California to Delaware at the 2023-06-15 meeting.

“Proposal 3 : The stockholders approved a proposed reincorporation pursuant to which the Company will change the state of its incorporation from California to Delaware, as set forth below: Votes Non-Votes 28,968,542 103,485 5,614 6,471,052”

Vivani Medical, Inc. shareholders approved Ratification of appointment of BPM, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.

“Proposal 2 : The stockholders, on an advisory basis, ratified the appointment of BPM, LLP as Vivani’s independent registered public accounting firm for the fiscal year ending December 31, 2023, as set forth below: Votes Non-Votes 35,330,026 73,358 145,310 0”

Vivani Medical, Inc. shareholders approved Election of five director nominees to serve until the 2024 Annual Meeting at the 2023-06-15 meeting.

“Proposal 1 : The stockholders elected each of the five director nominees to the Board of Directors of the Company (the “Board”) to serve until the 2024 Annual Meeting of Stockholders or until their successors have been duly elected and qualified, as set forth below: Director Name Votes Withheld Broker Non-Votes Gregg Williams 28,610,760 466,881 6,471,052 Aaron Mendelsohn 28,694,356 383,285 6,471,052 Dean Baker 29,005,584 72,057 6,471,052 Alexandra Larson 29,005,855 71,786 6,471,052 Adam Mendelsohn 29,007,613 70,028 6,471,052”

Vivani Medical, Inc. reported first quarter ended March 31, 2023 results: net income $6.3 million.

“Net Loss: The net loss was $6.3 million as compared to $3.9 million for the three-months ended March 31, 2023, and 2022, respectively.”

Vivani Medical, Inc. entered into Transition Funding, Support and Services Agreement with Cortigent, Inc. (effective 2023-03-19).

“On March 19, 2023, the Company and Cortigent, Inc. (“Cortigent”), a wholly owned subsidiary of the Company entered into a Transition Funding, Support and Services Agreement (the “TFSSA”), pursuant to which the Company has agreed to advance funds and provide or cause to be provided to Cortigent the services and funding intended to cover salaries and related costs, rent and other overhead in order to permit Cortigent to operate in substantially the same manner in which business operations of Cortigent were previously operated by Second Sight Medical Products, Inc., prior to the formation of Cortigent, which obligations will continue, in the case of the funding obligations, until the earlier of December 31, 2024 or the closing of an initial public offering of Cortigent (the "Funding Support Term").”

Vivani Medical, Inc. entered into a lease with 1350 South Loop, LLC valued at $2,676,311.40 per year (effective 2022-11-21).

“On November 28, 2022, Vivani Medical, Inc. (“Vivani”) entered into a 124-month lease agreement, effective November 21, 2022, with 1350 South Loop, LLC to rent premises for its new corporate headquarters with a commencement date of June 1, 2023. Vivani will rent approximately 43,645 square feet at a rate beginning at $2,676,311.40 per year, and increasing to $3,596,784.45 per year in 2033. In addition to the base rent, Vivani is also responsible for certain expenses and taxes. The premises is located at 1350 South Loop Road, Alameda CA 94502.”

Vivani Medical, Inc. reported the third quarter ended September 30, 2022 results: net income $1.4 million.

“Net income was $1.4 million in the third quarter of 2022, compared to a net loss of $3.5 million in the third quarter of 2021.”

Adam Mendelsohn was appointed as Director at Vivani Medical, Inc..

“On and as of the Effective Date, the Board appointed Adam Mendelsohn as a director of the Company.”

Lisa Porter was appointed as Chief Medical Officer at Vivani Medical, Inc..

“As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.”

Donald Dwyer was appointed as Chief Business Officer at Vivani Medical, Inc..

“As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.”

Truc Le was appointed as Chief Operating Officer at Vivani Medical, Inc..

“As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.”

Brigid A. Makes was appointed as Chief Financial Officer at Vivani Medical, Inc..

“As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.”

Adam Mendelsohn was appointed as Chief Executive Officer at Vivani Medical, Inc..

“As of the Effective Time, the Board appointed Adam Mendelsohn, as Chief Executive Officer of the Company, Brigid A. Makes, as Chief Financial Officer of the Company, Truc Le, as Chief Operating Officer of the Company, Donald Dwyer, as Chief Business Officer of the Company, and Lisa Porter, as Chief Medical Officer of the Company.”

Edward Sedo resigned as Acting Chief Accounting Officer at Vivani Medical, Inc..

“Scott Dunbar, Company’s Acting Chief Executive Officer and Edward Sedo, the Company’s Acting Chief Accounting Officer, resigned as officers of the Company.”

Scott Dunbar resigned as Acting Chief Executive Officer at Vivani Medical, Inc..

“Scott Dunbar, Company’s Acting Chief Executive Officer and Edward Sedo, the Company’s Acting Chief Accounting Officer, resigned as officers of the Company.”

Matthew Pfeffer resigned as Director at Vivani Medical, Inc..

“Pursuant to the Merger Agreement, immediately prior to and effective upon the Merger, Jonathan Will McGuire and Matthew Pfeffer, resigned from the Board and any respective committees of the Board to which they belonged, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices .”

Jonathan Will McGuire resigned as Director at Vivani Medical, Inc..

“Pursuant to the Merger Agreement, immediately prior to and effective upon the Merger, Jonathan Will McGuire and Matthew Pfeffer, resigned from the Board and any respective committees of the Board to which they belonged, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices .”

Edward Randolph resigned as Chief Operating Officer at Vivani Medical, Inc..

“On August 3, 2022, Second Sight Medical Products, Inc. (“Second Sight”) received notice from Edward Randolph, its Chief Operating Officer, that he will resign from his current position effective August 19, 2022.”

Jessy Dorn resigned as Vice President, Clinical and Scientific Affairs at Vivani Medical, Inc..

“On June 13, 2022, Second Sight Medical Products, Inc. received notice from Dr. Jessy Dorn, its Vice President, Clinical and Scientific Affairs, that she will resign from her current position effective July 15, 2022.”